GlassScriptPhysician profile
Emily R Wagner
NPI 1982019865
$4,206.94
in general payments reported to CMS, 2019-2025
35 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $846 · 2022: $1,442 · 2023: $681 · 2024: $692 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,846 · Education: $71.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,846.19 |
| Education | $71.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $627.13 | 2021-2025 | |
| Pfizer INC. | $442.04 | 2021-2025 | |
| Amgen INC. | $307.87 | 2021-2025 | Evenity, Prolia, Repatha |
| Teva Pharmaceuticals USA, INC. | $287.97 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $276.69 | 2021-2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.06 | 2021-2024 | Jardiance, Spiriva Respimat |
| Allergan, INC. | $202.41 | 2021 | |
| Novo Nordisk INC | $189.61 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $188.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $159.54 | 2021-2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $155.11 | 2021-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $109.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $99.15 | 2021-2023 | |
| Mylan Specialty L.P. | $95.57 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $90.85 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $83.87 | 2022 | |
| Harmony Biosciences LLC | $76.54 | 2022-2025 | Wakix |
| Otsuka America Pharmaceutical, INC. | $69.26 | 2022-2024 | Rexulti |
| Lundbeck LLC | $59.97 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $51.05 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.51 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $44.57 | 2022-2023 | Seglentis, Livalo |
| Glaxosmithkline, LLC. | $33.59 | 2021-2025 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $29.10 | 2025 | Voquezna |
| Amarin Pharma, INC. | $27.70 | 2021 | |
| Dexcom, INC. | $25.91 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $23.29 | 2021 | |
| Seqirus USA INC | $20.99 | 2024 | Fluad, Flucelvax |
| Neurocrine Biosciences, INC. | $20.63 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.90 | 2021 | |
| Boston Scientific Corporation | $15.48 | 2022 | |
| Viatris Specialty LLC | $14.63 | 2025 | Yupelri |
| Almatica Pharma LLC | $14.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.85 | 2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.